Salvia divinorum is not federally scheduled in the US — but banned in roughly 29 states. It works through kappa opioid receptors, not serotonin, making it pharmacologically distinct from every other psychedelic.
Yes — salvia divinorum produces hallucinations and profoundly alters consciousness, so it meets the functional definition of a psychedelic. But its mechanism is completely different from psilocybin, LSD, or DMT. Salvinorin A, its active compound, activates kappa opioid receptors rather than serotonin 5-HT2A receptors. This makes it pharmacologically unique: the only major naturally occurring psychedelic that is not serotonergic.
Salvia divinorum is not a federally controlled substance in the US. The DEA has designated it a 'drug and chemical of concern' since 2003 but has never formally scheduled it. However, approximately 29 states have passed their own criminal bans. It is fully criminalized in states like Florida, Texas, Illinois, Ohio, Michigan, and Tennessee. It is legal for adults in roughly 15 states including New York, Oregon, Washington, Nevada, and Massachusetts. California, Maine, and Maryland restrict sale to adults only.
When smoked or inhaled, effects begin within 30 seconds, peak at roughly 2 minutes, and typically resolve within 15–30 minutes. At higher doses the experience can last up to an hour. This is far shorter than psilocybin (4–6 hours), LSD (8–12 hours), or ayahuasca (4–6 hours), and comparable to smoked DMT. The rapid onset and offset make the experience particularly difficult to manage without preparation.
The primary physical risk is accidental injury from falls or disoriented movement during the experience — salvia causes complete loss of environmental awareness at peak. Unlike psilocybin, it often produces anxiety, fear, and dysphoria rather than euphoria. It is not addictive and does not activate mu-opioid receptors (no respiratory depression). Long-term effects in humans are not well-studied. People with a personal or family history of psychotic disorders should not use it.
The honest answer is: preclinical only. A 2025 systematic review of 82 animal studies found consistent signals for pain relief, addiction reduction, and neuroprotection after stroke. But as of 2026 there are no completed Phase 2 or Phase 3 human trials for any therapeutic indication. Two small Yale studies characterized the subjective effects and brain activity — they were mechanistic, not therapeutic.
Yes — but through a mechanism completely different from every other psychedelic. Salvia divinorum produces profound hallucinations and loses the user in an alternate reality for 15–30 minutes. That meets the functional definition of a psychedelic.
But its active compound, salvinorin A, does not touch serotonin receptors at all. Psilocybin, LSD, DMT, and mescaline all work by activating the serotonin 5-HT2A receptor. Salvinorin A activates kappa opioid receptors (KOR) — the same system activated by stress and the body's own dynorphins.2
This matters for both pharmacology and drug law. Drug discrimination studies confirm that animals cannot generalize salvinorin A's effects to LSD or other serotonergic psychedelics — they are not interchangeable.4 Salvinorin A is also the first known naturally occurring KOR agonist with no nitrogen atom — a structural anomaly unique in the plant kingdom.
Serotonergic psychedelics tend to produce emotionally rich, often euphoric experiences. KOR activation, by contrast, drives the brain's stress and dysphoria circuitry. This is why salvia experiences are so often disorienting and frightening rather than warm or connective — it is activating a fundamentally different system.
A February 2026 review in Biomedicines confirmed that salvinorin A has no direct serotonin receptor activity. It can indirectly modulate serotonin signaling at a systems level — but it is not a serotonergic psychedelic by any standard pharmacological definition.5
Salvia divinorum is not a controlled substance under federal law. It does not appear on any schedule of the Controlled Substances Act. The DEA designated it a “Drug and Chemical of Concern” around 2003 and has described it in enforcement publications, but has never initiated formal scheduling proceedings.1
Congress tried. The Hallucinogen Control Act of 2002 would have scheduled salvia federally, but it never passed. No subsequent federal bill has succeeded. The DOJ/DEA's own archive confirms: “Salvia divinorum is not controlled under the Controlled Substances Act.”
This means federal prosecution for simple possession or sale of salvia is not possible — a striking contrast with psilocybin, LSD, and DMT, which are all Schedule I substances.
Because federal law is silent, states moved on their own. The legislative wave started in Louisiana in 2005 and peaked around 2008–2012. As of 2026, approximately 29 states have criminalized salvia possession, sale, or cultivation.
The irony: salvia is criminally banned in more states than psilocybin — which now has legal, regulated access programs in Oregon and Colorado, plus a growing list of cities that have decriminalized it.
| Status | States |
|---|---|
| Criminally banned (~29 states + Guam) | Alabama, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Michigan, Minnesota, Mississippi, Missouri, Nebraska, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Wyoming + Guam |
| Age-restricted (sale to minors prohibited; adults may possess) | California, Maine, Maryland |
| No salvia-specific restriction | Alaska, Arizona, Idaho, Massachusetts, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon, South Carolina, Utah, Washington, West Virginia, DC, and others |
For comparison, psilocybin has legal, regulated access in Oregon and Colorado, and has been decriminalized in 30+ cities. Salvia has zero decriminalization initiatives and zero reform legislation pending anywhere in the US as of mid-2026.
See the psychedelic legal status by state tool for the broader landscape of which substances are legal in each state.
When smoked or inhaled, effects begin within 30 seconds and peak at roughly 2 minutes. The experience typically resolves within 15–30 minutes. At higher doses, effects can last up to an hour. The extremely rapid onset is a defining — and hazardous — characteristic.
At peak, users often report complete loss of environmental awareness, strong visual and auditory hallucinations, a sense of merging with objects or places, out-of-body experiences, and encounters with perceived entities or presences. Unlike most serotonergic psychedelics, the experience rarely feels emotionally connective — it is more commonly described as overwhelming or confusing.
A June 2025 review in the International Journal of Molecular Sciences found that pure salvinorin A inhaled at doses up to 12 mg produced no adverse vital sign effects and was rated “significantly less hazardous than morphine in humans” on acute toxicity metrics.3
Critically, salvinorin A does not activate mu-opioid receptors. This means no respiratory depression — the cause of death in opioid overdose. It is not classically addictive: animal models show it does not produce conditioned place preference (a standard test for abuse potential).
The primary physical risk is accidental injury during the experience. Because salvia causes complete loss of environmental awareness, users may fall, walk into objects, or behave in dangerous ways without registering it. A sober monitor is essential.
The dysphoric character of the experience means anxiety and panic are common, especially in unprepared users or at higher doses. At very high doses, animal models show depressogenic effects. People with a personal or family history of psychotic disorders or bipolar disorder should not use salvia. Long-term psychological effects in humans are not well-studied — a significant research gap.
A 2025 systematic review in Translational Psychiatry analyzed 82 animal studies of salvinorin A and found consistent signals across four areas:6
A meta-analysis of 21 animal studies found salvinorin A significantly increased pain thresholds at both 10 and 120 minutes post-administration. The mechanism — KOR activation — modulates pain signaling without activating mu-opioid receptors, suggesting potential for non-addictive analgesics.
Nine of 11 studies showed anti-addictive properties. Specifically, salvinorin A dose-dependently reduced cocaine-seeking behavior and opioid self-administration in primate models. This is a potentially important finding given the opioid crisis — KOR agonism can suppress reward-seeking without creating its own dependence pathway.
Thirteen studies consistently showed neuroprotective effects in stroke and hypoxia models, including significant reductions in brain edema. Intranasal delivery in rodent models reduced infarct volume and improved neurological outcomes.
Results in depression models were inconsistent with high heterogeneity — no overall antidepressant effect in the meta-analysis. The biphasic dose-response (antidepressant at low doses, potentially depressogenic at high doses) complicates this indication.
As of mid-2026, there are no completed Phase 2 or Phase 3 human therapeutic trials for salvinorin A. Two small Yale studies characterized its subjective effects and brain connectivity — they were mechanistic, not therapeutic. A registered trial for depression had enrolled only one participant at the time of the 2025 review.
This gap between preclinical promise and human research is notable. Psilocybin, by contrast, has FDA Breakthrough Therapy Designation and multiple positive Phase 3 trials. Salvia has neither regulatory interest nor organized advocacy.
If you want to volunteer for psychedelic research more broadly, see the guide to finding a psychedelic clinical trial.
| Feature | Classic psychedelics (psilocybin, LSD, DMT) | Salvia (salvinorin A) |
|---|---|---|
| Primary receptor | 5-HT2A (serotonin) | Kappa opioid receptor (KOR) |
| Chemical class | Alkaloids (contain nitrogen) | Neoclerodane diterpene (no nitrogen) |
| Duration (smoked) | Hours (DMT: 15–45 min) | 15–30 min (peak: ~2 min) |
| Mood bias | Often euphoric or emotionally resonant | Frequently dysphoric, disorienting |
| Abuse liability | Low (per research) | Very low (aversive phenomenology) |
| Federal scheduling | Schedule I (psilocybin, LSD, DMT) | Not scheduled |
| State bans | Psilocybin: legal in Oregon, Colorado; decrim in 30+ cities | Criminally banned in ~29 states; zero reform movement |
| Human therapeutic trials | Psilocybin: multiple Phase 3; MDMA: Phase 3 complete | None completed |
Salvia's legal landscape illustrates a core tension in drug scheduling: state bans were driven by media coverage, not pharmacological evidence. The legislative wave of 2005–2012 happened because salvia went viral on YouTube before policymakers had any scientific framework for evaluating it.
The result is that a substance with:
…is criminally banned in more states than psilocybin, which has now been through multiple FDA trials and two state legalization votes.
Advocacy organizations like MAPS, Decriminalize Nature, and the Drug Policy Alliance have not prioritized salvia. No organized lobbying for salvia research access exists as of mid-2026. The broader legal psychedelics landscape has moved on without it.
The psychedelic law and policy hub tracks the broader federal and state policy environment.
Get salvia research & policy updates
New trials, FDA decisions, and legal changes for salvia — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.